THC/CBD (Sativex®)

Delta-9-tetrahydrocannabinol (THC)/cannabidiol (CBD) (Sativex®) was added to the High Tech Arrangement on 1st October 2023. A Managed Access Protocol (MAP) is in place for THC/CBD (Sativex®). This outlines the criteria that must be satisfied in order for a patient to be recommended for reimbursement of THC/CBD (Sativex®) under the High Tech Arrangement.

The prescribing of THC/CBD (Sativex®) under the High Tech Arrangement is confined to consultant neurologists registered with the Irish Medical Council, who have agreed to the terms of the MAP and who have been approved by the HSE.

The approved prescriber must submit an application for individual reimbursement approval for each patient. Applications for individual reimbursement approval will only be considered from approved prescribers.

A copy of the HSE-Managed Access Protocol for THC/CBD (Sativex®) and a Clinical and Reimbursement Information Document can be found in the Related Files section below.

For further information, please contact